skip to main content
News and Events
  • New national initiative unites university students from coast to coast in honour of Canadian hero Terry Fox's legacy for cancer research

    by User Not Found | Sep 06, 2012

    • POSTER: (PDF) Click Here
    • VIDEO - Terry's CAUSE on Campus:
    • VIDEO - A Message from the Governor General of Canada: Launch of Terry's CAUSE on Campus:
    Vancouver, BC – For the first-time ever, students at universities across Canada are uniting from coast to coast to honour Canadian hero Terry Fox and to support his 32-year legacy of raising funds for cancer research.

    Terry’s CAUSE on Campus (TCC) is being launched today by the Terry Fox Foundation (TFF) and the Terry Fox Research Institute (TFRI) in partnership with a founding group of universities: Carleton University, Dalhousie University, McMaster University, Memorial University of Newfoundland, Queen’s University, Simon Fraser University, the University of Calgary, and the University of Toronto. (CAUSE stands for College and University Student Engagement.)

    Thousands of university students are expected to take part in the inaugural year, with events being held on campuses during September and early October in Alberta, British Columbia, Newfoundland & Labrador, Nova Scotia, and Ontario. All funds raised will go to TFF for investment in cancer research by TFRI.

    “We are thrilled with the enthusiasm and support that students, organizers and leaders at these institutions and others have shown for Terry’s CAUSE on Campus. Terry began planning and training for his Marathon of Hope while he was a first-year university student. He would be pleased and honoured to know that today students across Canada continue to be inspired by him and are joining together to support his dream – our dream – of ending cancer. We are extremely grateful to each and every person who is involved in this initiative and those who will be supporting Terry’s CAUSE on Campus. Your support will help us to make a difference,” said Mr. Darrell Fox, brother of Terry and a TFRI special advisor, who is spearheading the national initiative.

    “The Terry Fox Foundation is extremely pleased to be launching this new initiative in partnership with TFRI and our supporter institutions at universities from coast to coast,” said Ms Rhonda Risebrough, TFF provincial director (Alberta, Nunavut and Northwest Territories) and a member of the TCC executive committee. “It is a wonderful tribute to Terry Fox and his legacy by students who today are largely the same age that Terry was when he began training for his Marathon of Hope.”

    “TFRI is committed to improving outcomes for cancer patients and this new initiative will help to ensure that TFRI is able to invest in the most promising and excellent discovery and translational research in Canada as well as to train future cancer researchers to realize Terry’s dream. We are especially pleased that our university partners, whose researchers conduct the research we fund, are supportive of this new initiative. We hope Terry’s CAUSE on Campus will continue to grow across the country and even beyond, in countries around the world,” says Dr. Victor Ling, TFRI president and scientific director.

    Simon Fraser University, Terry’s alma mater, is leading the founding group of institutions in establishing Terry’s CAUSE on Campus. SFU holds a Terry Fox Day annually. “Terry attended Simon Fraser University as a kinesiology student when he was 18. At 19, he became a cancer patient. At 21, he was a hero. This national event is a great opportunity for current students – our country’s future leaders and researchers – to come together for a great cause and at the same time pay tribute to one of the country’s greatest heroes,” says Dr. Tim Rahilly, associate vice-president, students, Simon Fraser University. “His courage, determination and selflessness continue to inspire us all.”

    While McMaster and Queen’s universities have previously held Terry Fox events on campus, many of the participating institutions are launching events for the first time. In St. John’s, Newfoundland & Labrador where Terry’s Marathon of Hope began in 1980, students at Memorial University of Newfoundland will participate in a new campus run as part of their fall Orientation program. In Toronto, Ontario, students at the University of Toronto will participate for the first time in a run that will bring students from all three campus locations in the Greater Toronto Area to its Scarborough Campus. Dalhousie University and the University of Calgary will hold inaugural events on their campuses in October (as will UofT). Students at Carleton University in Ottawa will join forces with the Terry Fox Run in Ottawa, with two run times now set for September 16th. Other institutions are planning similar events. See the complete schedule below.

    In addition to the founding group, several other university and college institutions are expected to participate in Terry’s CAUSE on Campus in 2013. Complete details are available at www.terryfox.org/terryscauseoncampus and www.facebook.com/terryscause . Students at participating institutions can register online at www.terryfox.org/terryscauseoncampus .

    Other universities and colleges wishing to join Terry’s CAUSE on Campus can contact the Foundation directly at tcc@terryfoxrun.org.

    About TFF/TFRI:

    The Terry Fox Foundation (TFF) maintains the vision and principles of Terry Fox while raising money for cancer research through the annual Terry Fox Run, National School Run Day and other fundraising initiatives which, to date, have raised over $600 million worldwide. Launched in October 2007, The Terry Fox Research Institute (TFRI) is the brainchild of The Terry Fox Foundation (TFF). TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with over 50 cancer hospitals and research organizations across Canada. For more information, visit www.terryfox.org and www.tfri.ca.

    Note to media: Interviews with Mr. Fox, Dr. Ling and Ms Risebrough may be scheduled in advance via the media contacts below.

    Rhonda Risebrough
    Provincial Director
    The Terry Fox Foundation
    Tel: (403) 212-1336


    Kelly Curwin
    Chief Communications Officer
    Terry Fox Research Institute
    604-675-8223 Office; 778-237-8158 Cell

    2012 Inaugural Launch Schedule of Events for Terry’s CAUSE on Campus (Institution/Event Date)

    Carleton University/ Sept. 16
    Dalhousie University / Sept. 16
    McMaster University / Sept. 16
    Memorial University of Newfoundland/Sept 20
    Queen’s University/ Sept.16
    Simon Fraser University /Sept. 18
    University of Calgary / October 12
    University of Toronto/ Oct. 3
  • Nobel laureate Dr. Harald zur Hausen presents leadership seminar

    by User Not Found | Jul 27, 2012
    Vancouver, BC -- Nobel Laureate Dr. Harald zur Hausen's July 25, 2012 talk at the BC Cancer Research Centre in Vancouver drew about 400 listeners from on and off-site locations. Dr. zur Hausen gave an intellectually stimulating overview on the present state of knowledge about infectious agents (bacteria and viruses) and their contribution to the development of human cancer, as part of A Distinguished Leadership Seminar, presented jointly by the Terry Fox Research Institute and the BC Cancer Agency with support from UBC's Interdisciplinary Oncology Program. The lecture drew a multidisciplinary group of researchers and students into the audience. His talk encourages the audience to think deeply about areas where we do not yet understand what causes such high numbers of cancers.

    Now a professor emeritus at the German universities of Freiburg and Heidelberg, Dr. zur Hausen headed up the German cancer research centre for over 20 years, and was responsible for a number of changes there. In 2008 he was awarded the Nobel Prize for Medicine for his work on discovering the role of papilloma viruses. He is known internationally for his discovery that human papilloma virus (HPV) can cause cervical cancer. His work contributed to the development of a cervical cancer vaccine against HPV, introduced in 2006.

    In his talk, Dr. zur Hausen spoke about the different mechanisms of action of viruses on their human host, and how these contribute directly or indirectly to the development of specific cancers. He also presented data on the incidence of different cancers around the world, and discussed the eating habits of specific populations as fruitful areas of research in which to understand the interplay of environmental agents such as by-products of cooking, infectious agents in the development of cancer.
  • New pan-Canadian Terry Fox Research Institute network receives close to $4-million to find better tools to treat prostate cancer

    by User Not Found | Jul 25, 2012

    ATTENTION MEDIA: Montreal, QC -- Prostate cancer is the most commonly diagnosed cancer and the third-leading cause of cancer-related death in Canadian men. Screening has enabled earlier diagnosis of prostate cancer, but with three out of four men actually diagnosed with a non-lethal form, should they all undergo the same treatment? A new pan-Canadian network of prostate cancer researchers formed by the Terry Fox Research Institute aims to address this need with approximately $4-million provided by the Terry Fox Foundation and the Canadian Partnership Against Cancer. The funding was announced today at the CHUM Research Centre (CRCHUM).

    TFRI's Canadian Prostate Cancer Biomarker Network (CPCBN) brings together top scientists and clinicians at leading prostate cancer care and research centres in Quebec, Ontario and British Columbia to take aim at answering this question with the goal of providing better tools - including new and more effective biomarkers -- to treat and manage the disease. Over the next four years, the group will work to identify new ways to determine what forms of prostate cancer require immediate treatment and which don't, as well as how to better predict which patients, following treatment (surgery or radiation therapy), are at risk of their cancer progressing.

    Total funding for the network is $3,995,326, with the Partnership having provided $550,000.

    "We are extremely pleased to create this important biomarker research network and to provide a total of $3.5 million to address an important clinical question that both doctors who treat the disease and men who are diagnosed with it must consider," said Mr. Darrell Fox, senior advisor for the Terry Fox Research Institute (TFRI). "Having more tools at their disposal for decision making will help clinicians to better determine what treatment is best for a patient's particular prostate cancer."

    "Bringing together expertise and resources from across the country through this network will help to advance the science needed to improve the lives of Canadian men diagnosed with prostate cancer," says Dr. Robin Harkness, research specialist with the Canadian Partnership Against Cancer, a national organization funded by Health Canada to lead the implementation of a co-ordinated cancer strategy, and executive director of the Canadian Cancer Research Alliance. "This is one of several projects the Partnership has launched with the Terry Fox Research Institute with the practical goal of identifying emerging technologies that can improve the early detection and treatment of cancer and lead to better outcomes."

    "This new collaborative team has leadership and a track record across the research and clinical spectrums in understanding and treating prostate cancer and, collectively, they have excellent access to tissue samples and serum that are important to conducting studies to find new and effective biomarkers in this area. We appreciate the support of both the Terry Fox Foundation and the Canadian Partnership Against Cancer in funding this impressive network and the important work they are undertaking to improve care for patients," said Dr. Victor Ling, TFRI President and Scientific Director.

    Dr. Fred Saad, professor and chief of urology at the CHUM and director of prostate cancer research at the Montreal Cancer Institute-CRCHUM, leads the study. "We're excited about the opportunity to work together to identify significant biomarker combinations to be used with existing clinical tools to allow clinicians to better assess the risk of tumour progression of early-stage tumours before and after treatment. If this study goes as we hope it will, its impact will be profound -- reducing recurrence and improving quality of life for men who have the disease - as well as bringing economic and societal benefits through the more efficient and effective use of health resources," says Dr. Saad.

    He and project colleagues at CRCHUM will work with investigators at several partner institutions: McGill University, McGill University Health Centre (MUHC), the Research Institute of the MUHC , the Université Laval, the Centre hospitalier universitaire de Québec (CHUQ) in Quebec; Kingston General Hospital (Queen's University), Sunnybrook Health Sciences Centre, and the University Health Network (UHN) - Princess Margaret Hospital in Ontario; and the University of British Columbia, the Vancouver Prostate Centre and the Vancouver Coastal Health Research Institute in BC. The knowledge transfer will be performed in collaboration with experts from the three provinces as well as from Manitoba.

    The investigators will contribute to the studies in various ways, including providing clinical samples and data from patients having undergone surgery and radiotherapy, and also patients who have been put on active surveillance. This network will also be combining research expertise in biomarker and genetic profiling of cancers that will greatly increase the speed at which results will be obtained.

    The project will run until March 2016. The network has developed a knowledge translation component to reach out to interested partners and to engage the medical community in the implementation of their findings and including a biomarker-driven approach for diagnosing and managing the disease as an element in clinical decision making. These include: The Canadian Urology Association, NCIC Clinical Trials Group, The Canada Urologic Oncology Group, and Prostate Cancer Canada.

    About The Terry Fox Research Institute

    Launched in October 2007, The Terry Fox Research Institute (TFRI) is the brainchild of The Terry Fox Foundation (TFF). TFF maintains the vision and principles of Terry Fox while raising money for cancer research through the annual Terry Fox Run, National School Run Day and other fundraising initiatives which, to date, have raised over $600 million worldwide. TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with over 50 cancer hospitals and research organizations across Canada. TFRI headquarters are in Vancouver, BC. www.tfri.ca.

    About the CHUM

    The Centre hospitalier de l'Université de Montréal (CHUM) is the largest francophone teaching hospital in North America. Known for excellent care and the expertise of its specialists, every year it welcomes more than half a million patients not only from the greater Montreal region but also the entire province of Quebec. The essence of its mission is the application of innovative approaches to healthcare, the search for new knowledge, the promotion of health and the transfer of knowledge. Boasting a rich history, the CHUM is looking to the future with the ongoing construction of new facilities and its research centre in downtown Montreal, a comprehensive project on a single site valued at nearly $2.5 billion. The CHUM Research Centre will open its doors in 2013. It will be followed in 2016 by the unveiling of the new CHUM, a world-class teaching hospital in tune with its community where it plays a major role, in a socially aware perspective of sustainable development and concerted urban approach. It is also an active member of the Réseau universitaire intégré de santé (RUIS) de l'Université de Montréal. chumontreal.com

    For more information, contact:

    Kelly Curwin Director, Communications and Public Affairs
    Office: 604-675-8223
    Cell: 778-237-8158

    Sylvie Robitaille
    Communication Advisor
    Centre hospitalier de l'Université de Montréal (CHUM)
    Telephone: (514) 890-8000, extension 15262
    Pager: (514) 801-1101
  • 2011 New Investigator awardees receive $1.7 million

    by User Not Found | Jul 09, 2012

    (l-r): Dr. Sheila Singh, Dr. Jennifer Chan, Dr. Marianne Koritzinsky, Dr. Luke McCaffrey
    1) Dr. Sheila Singh, 2) Dr. Jennifer Chan, 3) Dr. Marianne Koritzinsky, 4) Dr. Luke McCaffrey

    More than $1.7 million is being awarded to four young cancer researchers under the 2011 Terry Fox New Investigator (NI) Awards program. Three of the selected investigators – Drs. Marianne Koritzinksy and Sheila Singh in Ontario and Dr. Luke McCaffrey in Quebec are funded solely by Terry Fox. The other -- Dr. Jennifer Chan in Alberta -- is funded [by] the Alberta Cancer Foundation in partnership with Terry Fox. This is the first time TFRI partners have supported and funded this prestigious award . The investigators will use their funding to further their work into the complex mechanisms of malignant tumours.

    While all four young researchers aspire to better cancer outcomes, their fields of study vary. One will be investigating the metabolism of low-oxygen cancer cells in hopes of disrupting their growth; another will be investigating novel gene therapies on aggressive brain tumours; a third will be looking at how tumour surfaces grow in breast cancer; and the fourth young researcher will be looking at the role of stem cell-like initiators in brain tumour formation.

    View brief summaries of the four recipients and their research.
    The Terry Fox Foundation has funded career awards for top new investigators for more than three decades. The awards are highly competitive and recipients are determined by a review committee of international scientific experts. The annual competition draws applications from the nation's best new talent and awards are made to those applicants selected to be the most outstanding. New last year and continuing this year, TFRI pairs new investigators with established scientists who are currently working on Terry Fox-funded projects. Each new investigator is linked to existing funded programs, and is supported by the principal investigators who have committed to mentoring the new researchers and integrating them into their research teams.
  • McGill trainees earn top honours at TFRI Scientific Meeting Poster Competition

    by User Not Found | Jun 26, 2012
    McGill trainees earn top honours at TFRI Scientific Meeting Poster Competition
    TFRI 2012 Poster Presentation
    (l-r): Chief Judge Dr. Robert Rottapel (Ontario Node Leader) with winners Dr. Carolina Ilkow (3rd place), Dr. Jennifer Knight (1st place), Ms Jill Ranger (2nd place), and Mr. Darrell Fox (TFRI Senior Advisor).

    A key highlight at TFRI's third annual scientific meeting (Victoria, BC, May 10-12, 2012) was the presentation of 77 posters from trainees who are working on Terry Fox-funded research in partner research laboratories across the country. Graduate students and post-doctoral fellows who submitted successful abstracts and are funded by the Terry Fox Foundation's New Frontiers Program Project Grants (PPGs) and Strategic Training In Health Research at CIHR grants or TFRI's Translational Projects, were awarded grants to travel to present research posters.

    Taking home top honours from this year's poster competition were McGill University's Goodman Cancer Research Centre trainees Dr. Jennifer Knight (1st place) and Ms Jill Ranger (2nd), along with Dr. Carolina Ilkow (3rd place) of the Ontario Health Research Institute. Dr. Ilkow is a PDF in Dr. John Bell's lab while Dr. Knight is a PDF supervised by Dr. Morag Park and Dr. Ranger is a graduate student supervised by Dr. William Muller. All three are affiliated with TFF-funded PPGs. Dr. Knight's poster was titled "Met synergizes with P53 loss to induce mammary tumours that possess features of claudin-low breast cancer."

    "Winning first was a great privilege. Like other trainees at the meeting, I take my research very seriously and have a great deal of passion for the work I do. It felt very special to have this recognized at the Terry Fox meeting and to be awarded my certificate by Darrell Fox," said Dr. Knight. She said she had positive and encouraging experience and now has added incentive to continue her career in cancer research.

    Their work , and that of their peers ,was judged by 20 participants - including TFRI executive members, funded investigators and invited guests from partner and funding institutions -- who attended the meeting.

    The awards went to those who scored highest in the following areas: abstract; poster content, appearance and organization; and oral presentation. Eligible posters were evaluated to determine a shortlist of 10 presenters who then each made a five-minute oral presentation at the meeting. Providing students with the opportunity to meet new people and share ideas, the two poster sessions proved to be a highlight of the meeting. The judges were impressed with the quality of the posters and the presentations made by the finalists.
  • Canadian "dream team" to tackle deadly brain cancer with $8.2 million from The Terry Fox Research Institute

    by User Not Found | Jun 05, 2012

    The Terry Fox Foundation and its partners in Alberta and across Canada

    ATTENTION MEDIA: CALGARY - They are a "dream team" comprised of some of the country's top minds in cancer research. They are harnessing their talent and technologies to find new treatments for the most common and deadly form of brain cancer among adults with an $8.2 million investment from The Terry Fox Research Institute (TFRI), The Terry Fox Foundation (TFF), Alberta Innovates - Health Solutions, the Alberta Cancer Foundation, Genome Canada, Genome BC and the BC Cancer Foundation.

    The investment, one of the largest ever made in Canada to research glioblastoma, will give hope to the approximately 2,600 Canadians annually who face a grim future when they are diagnosed with the disease. With current treatment, survival is about 15 months.

    "Today the Terry Fox Research Institute, The Terry Fox Foundation and our partners in Alberta and across Canada are providing a total of $8.2 million over five years to this pan-Canadian collaboration of scientists and clinician-scientists from Alberta, British Columbia and Ontario. We are pleased to have so many funders supporting this great new team in its work to find new and effective treatments for this deadly disease. This is very important and necessary research," says Dr. Victor Ling, TFRI's president and scientific director.

    TFRI and TFF are contributing nearly $3.1 million to the project with Alberta Innovates - Health Solutions (AIHS) providing $2 million, Alberta Cancer Foundation providing $1.9 million, and Genome Canada investing $612,000. Genome BC is contributing $306,000 and the BC Cancer Foundation is investing $250,000.

    The announcement is being made at the University of Calgary's Faculty of Medicine. Researchers there will lead the national initiative and receive $4.1 million to fuel their research.

    For over three decades, glioblastoma treatment has remained largely unchanged. The research team is focusing on developing promising new drugs. Currently there is no drug development pipeline that brings potentially useful new agents to the clinic for testing against glioblastoma. This team will help to address that gap and projects that the first of the new drugs discovered from this research will be ready for clinical trials in two to four years.

    "We at AIHS are proud that our scientists and clinical scientists are leading this powerful national collaboration," says Alberta Innovates - Health Solutions CEO Dr. Jacques Magnan. "By pooling the considerable talents and expertise of a team of cancer biologists, neurologists and cancer specialists, we can better tackle this devastating disease."

    "This is a deadly disease with so few treatment options that we are extremely pleased to be investing in a collaborative and focused research strategy that we believe will make a difference for patients," says Myka Osinchuk, CEO of the Alberta Cancer Foundation. "We are excited to be part of a national project that will push the pace of discovery, right here in Alberta."

    "Today we are showing how the power of team work, 21st century technology and innovation - our very best research traits - combine to take on a deadly disease that strikes too many people much too soon," says Pierre Meulien, PhD, President and CEO of Genome Canada. "Only through our ability to advance the latest technology developments to the clinical setting can we demonstrate how genomics can help improve cancer survival."

    Dr. Gregory Cairncross, head of the department of clinical neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor Research, will lead the project. "There is nothing more personal than your brain. Although we've made some progress in treating glioblastoma, it has not been dramatic. This is a disease where survival is measured in months," says Dr. Cairncross. "Our team integrates researchers and centres in Canada with different and complementary strengths and we've come together to focus on the illness itself. We don't see any other way forward other than through research because there seems to be no way to prevent glioblastoma. We have a chance to make a difference and we are hopeful that we will."

    The Alberta team involved in the project, led by co-investigators Samuel Weiss, PhD (University of Calgary's Hotchkiss Brain Institute) and Stephen Robbins, PhD (University of Calgary's Southern Alberta Cancer Research Institute and Clark H. Smith Brain Tumour Research Centre) and their colleagues, are focused on developing and providing laboratory cell models that closely resemble, from a molecular and microscopic perspective, glioblastoma tumours. Using tumours obtained from patients, the team is successfully growing brain tumour initiating cells (BTICs) in the laboratory that retain the genetic makeup of their cancer, thereby setting the stage for this new TFRI program.

    Researchers in British Columbia and Ontario will analyse models of glioblastoma from the Alberta group to determine their molecular genetic composition and to target compounds that might help control tumour growth and development. The goal is to identify new drugs to test in the clinic on different brain tumour subtypes, advancing toward personalizing treatment for this form of cancer.

    In Vancouver, Dr. Marco Marra (BC Cancer Agency Genome Sciences Centre, the University of British Columbia) will lead the genome analyses with co-investigators at the BC Cancer Agency's Genome Sciences Centre. In Ontario, University of Toronto researcher Dr. David Kaplan (The Hospital for Sick Children (SickKids)) will oversee the laboratory work where thousands of potentially helpful drugs will be screened for activity against BTICs from Calgary. Also in Ontario, Dr. Warren Mason (University Health Network) will lead the human clinical trials in association with the NCIC Clinical Trials Group and clinical colleagues at the Tom Baker Cancer Centre and BC Cancer Agency. The British Columbia and Ontario teams will share the remainder of the funding.

    Other partners involved in the project include: Genome Alberta, the University of British Columbia, the BC Cancer Agency, SickKids (Toronto), Mount Sinai Hospital (Toronto) the University Health Network (Toronto), the Ontario Institute for Cancer Research, the University of Toronto, and the NCIC-Clinical Trials Group.

    Dr. Cairncross says inherited genes and the aging process likely play a role but that there is currently no way to modify the risk of getting glioblastoma, most often diagnosed in older adults. "It's not an illness over which we have much control. One can't avoid it. It comes out of the blue, often to people who are previously healthy, just minding their own business."

    About The Terry Fox Research Institute
    Launched in October 2007, The Terry Fox Research Institute is the research arm of The Terry Fox Foundation. TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with over 50 cancer hospitals and research organizations across Canada as MOU partners. TFRI headquarters are in Vancouver, BC.

    About The Terry Fox Foundation
    The Terry Fox Foundation maintains the vision and principles of Terry Fox while raising money for cancer research through the annual Terry Fox Run, National School Run Day and other fundraising initiatives. To date, over $600 million has been raised worldwide for cancer research in Terry Fox's name. The first Terry Fox Run was held in 1981, with The Terry Fox Foundation being created in 1988. Its national headquarters are located in Chilliwack, BC and it has offices in 9 provinces.

    About The University of Calgary
    The University of Calgary is a leading Canadian university located in the nation's most enterprising city. The university has a clear strategic direction - "Eyes High" - to become one of Canada's top five research universities by 2016, grounded in innovative learning and teaching and fully integrated with the community of Calgary.
    For more information, visit www.ucalgary.ca

    About Alberta Innovates - Health Solutions
    AIHS is a publicly funded corporation with a vision to transform health and well being through research and innovation. We provide leadership for Alberta's health research and innovation enterprise by funding and fostering research and innovation. Alberta's Health Research and Innovation Strategy provides the framework for how we provide support in three core areas: highly skilled people; knowledge translation; and innovation platforms (systems to optimize the impact of research).

    About The Alberta Cancer Foundation
    The Alberta Cancer Foundation is Alberta's own. It was established to advance cancer research province-wide and to directly support Alberta's 17 cancer centres, including the Cross Cancer Institute and Tom Baker Cancer Centre. The Alberta Cancer Foundation acts on the knowledge that a cancer-free future is achievable and that when we get there depends on the focus and energy we put to it today.

    About Genome Canada
    Genome Canada is a non-profit corporation employing an innovative business model based on funding and managing large-scale, multidisciplinary, internationally peer-reviewed genomics research projects in areas such as agriculture, forestry, fisheries, the environment and human health.
    For more information, visit www.genomecanada.ca

    About Genome BC
    Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast, and manages a cumulative portfolio of over $550M in research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries, agriculture, environment, bioenergy, mining and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada.

    About BC Cancer Foundation
    The BC Cancer Foundation is the bridge that connects philanthropic support and research breakthroughs in cancer knowledge. As the fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province, we enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia. We fund with the goal of finding solutions.


    For more information, contact:

    Kelly Curwin
    Chief Communications Officer
    Terry Fox Research Institute
    778-237-8158 (cell)

    Marta Cyperling
    Media Relations Manager
    UCalgary Faculty of Medicine

    Karen Thomas
    Media Relations Specialist
    Alberta Innovates – Health Solutions
    1-877-423-5727 x 225
    1-403-651-1112 (cell)

    Phoebe Dey
    Communications Manager
    Alberta Cancer Foundation
    780-700-6120 (cell)

    Marlene Orton
    Genome Canada
    Director, Media and Communications
    (613) 751-4460 ext./poste 119
    (613) 295-1476 (Cell/Cellule)

    Julia White
    Communications Officer
    Genome British Columbia
    Allison Colina
    Communications Specialist
    BC Cancer Foundation
    604-802-6984 (cell)

    Doris Sun
    Communications Officer - BC Cancer Agency
    Provincial Health Services Authority
    604-675-8257; 778-877-6643 (cell)

    Suzanne Gold
    Senior Communications Specialist - Media Relations
    Communications & Public Affairs
    The Hospital for Sick Children (SickKids)
    416-813-7654 ext. 2059

    Jane Finlayson
    Senior Public Affairs Advisor
    Princess Margaret Hospital
    University Health Network

    Jim Oldfield
    Communications Officer
    Office of Strategy, Communications and External Relations
    University of Toronto Faculty of Medicine
  • Terry Fox Research Institute announces appointment of Iain R.V. MacKay to its Board of Directors

    by User Not Found | May 01, 2012
    Vancouver, BC - The Terry Fox Research Institute (TFRI) is pleased to announce the appointment of Mr. Iain MacKay, a retired Vancouver chartered accountant, to its Board of Directors commencing May 1.

    "Iain has an impeccable track record and an accomplished history of service to community throughout his long and impressive career. We are extremely pleased to have him join our Board. His financial leadership and business acumen, as well as his experience within the health care sector and cancer research specifically, will bring new strengths to our Institute and its operation," said Dr. Victor Ling, President and Chair of the Board of Directors for TFRI. "TFRI will benefit substantially from Iain's wisdom and experience. We are grateful he has chosen to spend some of his retirement in service to Terry Fox."

    Mr. MacKay retired in 2010 as head of the Vancouver-based firm MacKay LLP Chartered Accountants, a practice he started in 1970 and which, at the time of his retirement, included 40 partners and over 200 staff. The firm has grown to include offices in Vancouver, Whitehorse, Yellowknife, Edmonton, Kelowna, Surrey and Calgary.

    Born in the UK and educated in Scotland, Mr. MacKay immigrated to Canada in 1964. After graduating as a CA, he moved to the Yukon. During his 10 years there, he was an active member of the community, serving as president of the Whitehorse Chamber of Commerce, founding president of the Yukon Institute of Chartered Accountants, MLA in the Yukon Legislative Assembly and Leader of the Opposition.

    Upon returning to Vancouver, he served in several capacities: finance chair of the BC Liberal Party, council member with the BC Institute of Chartered Accountants. He also served on the boards for St. George's School (including two years as chair), the BC Cancer Agency and the BC Cancer Foundation (including four years as chair).

    "It is both a privilege and an honour to be joining this young, new Institute named for Terry Fox. I am looking forward to learning more about the research undertaken in Terry's name across this great nation. My focus will be to provide strategic financial and business leadership that will help to most make the difference for the Institute as it moves forward. Cancer research has always been near and dear to my heart and I am looking forward to spending time on this exceptionally worthy cause."

    Mr. MacKay has been awarded the honorary designation of "FCA" by both the Yukon and BC Institutes of Chartered Accountants, the Queen's Jubilee Medal and the BC Community Service Award. He currently sits on the boards of two local charities.

    Mr. MacKay enjoys sailing, golf and travel. He is married, has six children and five grandchildren.

    In addition to Dr. Ling and Mr. MacKay, Dr. Christopher Paige, vice-president research, University Health Network, and Mr. Darrell Fox, Terry's younger brother, serve on the Institute's Board.
  • Terry-Fox funded research at Princess Margaret Hospital finds oxygen in tumours predicts prostate cancer recurrence

    by User Not Found | Mar 31, 2012

    Terry Fox-funded prostate cancer researchers at the Princess Margaret Hospital in Toronto have made a finding about oxygen levels in tumours that could change the way that prostate cancer is treated. Work by Dr. Michael Milosevic and colleagues is published today in Clinical Cancer Research. Their work is supported through funds receive under a Terry Fox New Frontiers Program Project Grant.

    Click here for more information

  • Terry Fox inducted into Canadian Medical Hall of Fame as "medical hero"

    by User Not Found | Mar 21, 2012

    Canadian icon Terry Fox is one of seven laureates lauded this year as a medical hero and named to the Canadian Medical Hall of Fame on March 21 at the CMHF's 2012 induction ceremony in Toronto. Three others were also inducted posthumously, including Dr. John Macleod, who shared the 1923 Nobel Prize in Physiology or Medicine with Dr. Frederick Banting for their work on the discovery of insulin.

    The 2012 inductees recognized with Fox were Dr. John James Macleod (1876-1935); Dr. Armand Frappier (1904-1991), Dr. Peter Macklem (1931-2011), Dr. John Dirks, Dr. F. Clarke Fraser and Dr. Lap-Chee Tsui. These seven distinguished Canadians, whose extraordinary contributions to health care and health research have made the world a better place, join 88 others who are among the select few to be given the honour since 1994.

    Fox was recognized as "builder" for his work to raise money for cancer research. "For one magnificent summer, an entire nation ran stride for painful stride with a young man whose desire was to run across Canada to raise money for cancer research, and in doing so, to meet the challenge of the disease that took his leg. Terry Fox did that, calling his dream the Marathon of Hope and uniting a nation around a common cause. And although the cancer he so bravely fought took his life, his legacy was just the beginning. Today hundreds of millions of dollars have been raised globally for cancer research through The Terry Fox Run, held across Canada and around the world," said the CMHF citation.

    Read the full CMHF citation about Terry Fox here.

    Family members Rolland (Rolly) and Fred Fox, Terry's father and older brother, attended the ceremony. TFRI's board member Dr. Christopher Paige and Quebec Node Leader Dr. Anne-Marie Mes-Masson also attended.

    "The Marathon of Hope raised $24 million for cancer research in 1980, yet Terry was penniless. In fact, I think he was rich. Rich with the knowleddge that he had tried his very best and that he had run until he could run no more. Rich with the knowledge that he had shared his definition of giving: to give and not want or expect anything in return. And he was rich and content with the knowledge that his vision of eliminating cancer through medical research was now in the hands of others to continue," said the elder Fox.

    Rolly Fox said his family admires the work of the CMHF and held a great appreciation of their efforts to recognize medical heroes and health care difference makers in Canada. He said he and Fred were thankful to be in the presence of other Canadian Medical Hall of Fame inductees who have devoted their lives to advancing health care. "Terry would, with pride, accept this induction, but be quick to acknowledge the Terry Fox volunteers for running with him in 1980 and every year since," said Rolly.

    "Terry is the youngest-ever inductee into the CMHF and the first whose achievements were non-professional. From my perspective, Terry has been chosen primarily because of his heroic accomplishment and the impact of the movement that he started. Only four other individuals who were not physicians or scientists have been inducted into the CMHF -- Peter Lougheed, Marc Lalonde, Tommy Douglas and Saint Marguerite d'Youville --," says Carol Cass, a member of the CMHF's Laureate's Selection Committee. Cass is TFRI's Alberta node leader and an emeritus professor of oncology and adjunct professor of biochemistry at the University of Alberta.

    Terry joins other notable laureates including: Drs. Charles Best, Norman Bethune, Fraser Mustard, Ernest McCulloch, James Till and Michael Smith.

    To view short video documentaries about Terry Fox and the 2012 laureates, click here.

    Click here for more information about the 2012 CMHF.

  • Signing in Singapore strengthens research capacity and Terry Fox legacy

    by User Not Found | Feb 22, 2012
    Singapore - Ties to Terry Fox and his cancer research legacy were strengthened in Singapore in February 2012 with the signing of a Memorandum of Understanding between the Terry Fox Research Institute and two leading research organizations.

    TFRI President and Scientific Director Dr. Victor Ling travelled to Singapore to sign the agreement with representatives from the National University Hospital/National University Cancer Institute, Singapore (NUHIS) and the National Cancer Centre of Singapore (NCCS). The agreement provides for all three parties to jointly share responsibility for and oversight of the scientific investment and research activity conducted there with funds raised from the annual Terry Fox Run held in Singapore.

    "This new agreement formalizes the joint goals of the agencies involved and the donors who support the annual run to ensure that the best research projects are undertaken and supported," said Dr. Ling. "We look forward to working with our new research partners in Singapore and we thank everyone here who has helped to make this annual run a success. Together we are working to improve cancer outcomes for citizens in Singapore."

    "Asia currently bears half of the world's cancer burden, and this is expected to rise within our lifetime. It is the leading cause of death in Singapore, and we need to invest significantly in understanding this disease if we are going to reverse this. This is especially so as some cancers behave differently between Asia and the West, and drug efficacy and toxicity may also differ between different populations in the world," said Dr. John Wong, director of Singapore's National University Cancer Institute.

    "We are deeply grateful to the Terry Fox Run for helping raise awareness and funds for cancer research. This Memorandum of Understanding brings together the Terry Fox Research Institute, National University Cancer Institute, Singapore and the National Cancer Centre, Singapore to work on developing better ways to prevent, diagnose, and treat this disease, and by doing so, do we honor Terry's memory and all those who have lost their loved ones to cancer."

    "The signing of the MOU will ensure that the funds raised by the Singapore Cancer Society and the Canadian Association of Singapore through the annual Terry Fox Run will be used to maximize the benefits to cancer research locally here in Singapore. We look forward to a strong partnership going forward," said Mr. Gray.

    "We commend our run organizers and supporters in Singapore for supporting Terry Fox and for helping to make a difference in continuing Terry's dream of a world without cancer," said Judith Fox-Alder, director of the Terry Fox International Run Program.

    In 2011, the run raised $90,000 for cancer research. Since 1993 (and including 2011), over $3.3 million has been raised through annual Terry Fox Runs in Singapore. Funding has supported research into novel therapies for specific blood cancers, and the molecular causes of colon and kidney cancers.
Back to Top